JUAN LOMBEIDA: Open Payments
NPI 1043434202 · FAYETTEVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$521 in 32 payments from 15 companies in 2025. Trend: 2023 $307 · 2024 $552 · 2025 $521
Food & beverage: $521
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 4 | $72 |
| Iovance Biotherapeutics, Inc. | 4 | $61 |
| Janssen Biotech, Inc. | 3 | $54 |
| Novartis Pharmaceuticals Corporation | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 3 | $49 |
| JAZZ PHARMACEUTICALS INC. | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Geron Corporation | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Merck Sharp & Dohme LLC | 1 | $18 |
Products named: Amtagvi, RYBREVANT, LIBTAYO, RYTELO, AYVAKIT, ZIIHERA, SCEMBLIX, PLUVICTO.
Industry payments across AR — which companies pay providers there.
